A Phase 3 Open-Label Immunogenicity and Safety Study of 2-Dose Regimens of a 9vHPV Vaccine (V503) in Chinese Girls 9 Through 14 Years of Age With a Comparison to 3-Dose Regimen of V503 in Chinese Women 20 Through 26 Years of Age
Latest Information Update: 05 Sep 2022
At a glance
- Drugs V 503 (Primary)
- Indications Human papillomavirus infections
- Focus Pharmacodynamics; Registrational
- Sponsors Merck Sharp & Dohme Corp.
Most Recent Events
- 01 Sep 2022 Planned End Date changed from 27 Dec 2029 to 3 Aug 2029.
- 01 Sep 2022 Planned primary completion date changed from 27 Dec 2029 to 3 Aug 2029.
- 01 Sep 2022 Status changed from recruiting to active, no longer recruiting.